Triple

T6006074
Position Surface form Disambiguated ID Type / Status
Subject ICH Q10 Pharmaceutical Quality System E133712 entity
Predicate supports P516 FINISHED
Object ICH Q8 Pharmaceutical Development E131967 NE FINISHED

Named-entity recognition

Before disambiguation, gpt-5-mini classified whether the object phrase is a named entity — the step behind the object's NE type shown above.

Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ICH Q8 Pharmaceutical Development | Statement: [ICH Q10 Pharmaceutical Quality System, supports, ICH Q8 Pharmaceutical Development]

Disambiguation candidates (1 decision)

The exact options the model was shown at each disambiguation step, with the option it chose highlighted — the evidence behind this triple's disambiguated ids.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: ICH Q8 Pharmaceutical Development
Context triple: [ICH Q10 Pharmaceutical Quality System, supports, ICH Q8 Pharmaceutical Development]
  • A. ICH Q8 Pharmaceutical Development chosen
    ICH Q8 Pharmaceutical Development is an international guideline that outlines a systematic, science- and risk-based approach to pharmaceutical product and process development, forming a core part of the ICH quality framework.
  • B. ICH Q11 Development and Manufacture of Drug Substances
    ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.
  • C. ICH Q10 Pharmaceutical Quality System
    ICH Q10 Pharmaceutical Quality System is an international guideline that establishes a comprehensive, lifecycle-based framework for pharmaceutical quality management to ensure consistent product quality and regulatory compliance.
  • D. ICH Q3A Impurities in New Drug Substances
    ICH Q3A Impurities in New Drug Substances is an international regulatory guideline that sets quality standards and thresholds for identifying, reporting, and controlling impurities in new active pharmaceutical ingredients.
  • E. ICH Q9 Quality Risk Management
    ICH Q9 Quality Risk Management is an international guideline that provides a systematic, science- and risk-based approach to identifying, evaluating, and controlling quality risks throughout the lifecycle of pharmaceutical products.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

Stage Batch ID Job type Status
creating batch_69c00872444c8190bfaf1739dcec765c elicitation completed
NER batch_69c04f128354819088971ee398cbda77 ner completed
NED1 batch_69c11365741c819097a43a49dd2428c1 ned_source_triple completed
Created at: March 22, 2026, 4:06 p.m.